Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Iteos Therapeutics Inc (ITOS)

Iteos Therapeutics Inc (ITOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates GlobeNewswire - Tue Nov 12, 6:00AM CST

ITOS : 8.14 (+3.69%)
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress GlobeNewswire - Thu Oct 24, 6:00AM CDT

ITOS : 8.14 (+3.69%)
NCR Atleos Set to Join S&P SmallCap 600 PR Newswire - Wed Oct 11, 2023

/PRNewswire/ -- NCR Atleos Corp. (NYSE: NATL) will replace iTeos Therapeutics Inc. (NASD: ITOS) in the S&P SmallCap 600 effective prior to the opening of...

SPGI : 511.73 (+1.71%)
ITOS : 8.14 (+3.69%)
NATL : 30.75 (+1.59%)
NCR : 27.08 (+3.24%)
VYX : 14.65 (+3.17%)
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action FinancialNewsMedia - Thu Jun 8, 2023

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – June 8, 2023 – USA News Group  –  By utilizing newly developed novel mechanisms, biotech researchers and scientists are...

ONCY : 0.9809 (-1.76%)
ONC.TO : 1.39 (-0.71%)
GILD : 89.74 (+1.25%)
ITOS : 8.14 (+3.69%)
GSK : 33.62 (+0.81%)
PGEN : 0.9199 (+9.94%)
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action PR Newswire - Thu Jun 8, 2023

/PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against...

ONC.TO : 1.39 (-0.71%)
ONCY : 0.9809 (-1.76%)
GILD : 89.74 (+1.25%)
ITOS : 8.14 (+3.69%)
GSK : 33.62 (+0.81%)
PGEN : 0.9199 (+9.94%)
Novel Mechanisms Leading the Charge in Fight Against Cancer, Opening Door to New Drugs & Therapies BayStreet.ca - Thu Jun 8, 2023

USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer. A study put out by researchers at the University of...

ONCY : 0.9809 (-1.76%)
ONC.TO : 1.39 (-0.71%)
GILD : 89.74 (+1.25%)
ITOS : 8.14 (+3.69%)
GSK : 33.62 (+0.81%)
PGEN : 0.9199 (+9.94%)
iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update Globe Newswire - Wed Aug 10, 2022

- Began enrolling patients with head and neck squamous cell carcinoma in Phase 2 trial expansion evaluating anti-TIGIT monoclonal antibody,...

ITOS : 8.14 (+3.69%)
iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference Globe Newswire - Tue Aug 2, 2022

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 02, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical...

ITOS : 8.14 (+3.69%)
Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer Business Wire - Mon Jun 13, 2022

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announced...

ITOS : 8.14 (+3.69%)
iTeos Reports First Quarter 2022 Financial Results and Provides Business Update Globe Newswire - Thu May 12, 2022

Enrolling patients with multiple myeloma in clinical trial of anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A in monotherapy and in combination with...

ITOS : 8.14 (+3.69%)

Barchart Exclusives

1 EV Stock Under $10 With 25% Upside Potential Barchart - 1 hour ago
This charging stock has been under heavy pressure lately amid concerns over the fate of EV tax credits. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot